NASDAQ:LNSR LENSAR (LNSR) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free LNSR Stock Alerts $3.24 -0.19 (-5.54%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$3.10▼$3.6050-Day Range$3.02▼$5.0052-Week Range$1.80▼$5.30Volume76,316 shsAverage Volume33,861 shsMarket Capitalization$36.94 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get LENSAR alerts: Email Address LENSAR MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside146.9% Upside$8.00 Price TargetShort InterestHealthy0.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.95 out of 5 starsMedical Sector377th out of 913 stocksMedical Devices Industry1st out of 2 stocks 3.5 Analyst's Opinion Consensus RatingLENSAR has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLENSAR has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.73% of the float of LENSAR has been sold short.Short Interest Ratio / Days to CoverLENSAR has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LENSAR has recently decreased by 12.03%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLENSAR does not currently pay a dividend.Dividend GrowthLENSAR does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LNSR. Previous Next 2.6 News and Social Media Coverage News SentimentLENSAR has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for LENSAR this week, compared to 0 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LENSAR insiders have not sold or bought any company stock.Percentage Held by Insiders38.52% of the stock of LENSAR is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.15% of the stock of LENSAR is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of LENSAR is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LENSAR is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLENSAR has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About LENSAR Stock (NASDAQ:LNSR)LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Read More LNSR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LNSR Stock News HeadlinesApril 21, 2024 | morningstar.comLENSAR Inc Ordinary Shares LNSRApril 1, 2024 | businesswire.comLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 7, 2024 | finance.yahoo.comLENSAR, Inc. (NASDAQ:LNSR) Just Reported Earnings, And Analysts Cut Their Target PriceMarch 5, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: 89bio (ETNB), UnitedHealth (UNH)March 5, 2024 | finance.yahoo.comLENSAR, Inc. (NASDAQ:LNSR) Q4 2023 Earnings Call TranscriptMarch 5, 2024 | finance.yahoo.comLENSAR Full Year 2023 Earnings: EPS Beats ExpectationsMarch 4, 2024 | finance.yahoo.comLENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 1, 2024 | businesswire.comLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | businesswire.comLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | msn.comLENSAR Q4 2023 Earnings PreviewFebruary 28, 2024 | markets.businessinsider.comNavigating 6 Analyst Ratings For Viridian TherapeuticsFebruary 26, 2024 | businesswire.comLENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024February 26, 2024 | businesswire.comLENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024February 22, 2024 | benzinga.comLENSAR Stock (NASDAQ:LNSR), Short Interest ReportFebruary 7, 2024 | msn.comLENSAR Board Approves Executive Bonuses for 2023 PerformanceJanuary 25, 2024 | finance.yahoo.comLENSAR Decline Means Insider Profits Down To US$42kNovember 12, 2023 | finance.yahoo.comLENSAR, Inc. (NASDAQ:LNSR) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comLENSAR Inc (LNSR) Reports 26% Revenue Growth in Q3 2023 Amid Expanding ALLY System InstallationsNovember 9, 2023 | finance.yahoo.comLENSAR Reports Third Quarter 2023 Results and Provides Business UpdateNovember 8, 2023 | benzinga.comLENSAR's Earnings OutlookNovember 2, 2023 | finance.yahoo.comLENSAR to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023October 11, 2023 | uk.sports.yahoo.comGerman tattoo artist taken hostage by Hamas ‘still alive’ says her motherOctober 11, 2023 | finance.yahoo.comA Piece Of The Puzzle Missing From LENSAR, Inc.'s (NASDAQ:LNSR) Share PriceSeptember 14, 2023 | finance.yahoo.comWill LENSAR (NASDAQ:LNSR) Spend Its Cash Wisely?August 18, 2023 | finance.yahoo.comSeveral Insiders Invested In LENSAR Flagging Positive NewsSee More Headlines Receive LNSR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENSAR and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/04/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:LNSR CUSIPN/A CIK1320350 Webwww.lensar.com Phone888-536-7271FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+146.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,380,000.00 Net Margins-34.11% Pretax Margin-34.11% Return on Equity-40.53% Return on Assets-21.83% Debt Debt-to-Equity RatioN/A Current Ratio3.99 Quick Ratio2.64 Sales & Book Value Annual Sales$42.16 million Price / Sales0.88 Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book1.09Miscellaneous Outstanding Shares11,395,000Free Float7,006,000Market Cap$36.92 million OptionableOptionable Beta0.47 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Nicholas T. Curtis (Age 67)President, CEO & Director Comp: $974.29kMr. Thomas R. Staab II (Age 56)CPA, CFO & Secretary Comp: $612.55kMr. Alan B. Connaughton (Age 52)Chief Operating Officer Comp: $650.62kMs. Kendra W. Wong (Age 44)Principal Accounting Officer Key CompetitorsCo-DiagnosticsNASDAQ:CODXLucid DiagnosticsNASDAQ:LUCDModular MedicalNASDAQ:MODDSpectral AINASDAQ:MDAIGBSNYSE:GBSView All CompetitorsInsiders & InstitutionsDCF Advisers LLCSold 42,002 shares on 2/13/2024Ownership: 2.138%Brandes Investment Partners LPBought 6,827 shares on 2/9/2024Ownership: 2.015%Gary M WinerBought 300 shares on 11/22/2023Total: $630.00 ($2.10/share)Gary M WinerBought 500 shares on 11/15/2023Total: $1,075.00 ($2.15/share)Gary M WinerBought 1,000 shares on 11/10/2023Total: $2,130.00 ($2.13/share)View All Insider TransactionsView All Institutional Transactions LNSR Stock Analysis - Frequently Asked Questions Should I buy or sell LENSAR stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LENSAR in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LNSR shares. View LNSR analyst ratings or view top-rated stocks. What is LENSAR's stock price target for 2024? 1 brokerages have issued 12 month target prices for LENSAR's shares. Their LNSR share price targets range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 146.9% from the stock's current price. View analysts price targets for LNSR or view top-rated stocks among Wall Street analysts. How have LNSR shares performed in 2024? LENSAR's stock was trading at $3.51 at the beginning of 2024. Since then, LNSR stock has decreased by 7.7% and is now trading at $3.24. View the best growth stocks for 2024 here. Are investors shorting LENSAR? LENSAR saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 77,300 shares, an increase of 85.8% from the March 15th total of 41,600 shares. Based on an average trading volume of 43,700 shares, the short-interest ratio is presently 1.8 days. Approximately 0.8% of the shares of the stock are short sold. View LENSAR's Short Interest. When is LENSAR's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our LNSR earnings forecast. How were LENSAR's earnings last quarter? LENSAR, Inc. (NASDAQ:LNSR) announced its earnings results on Monday, March, 4th. The company reported ($0.22) earnings per share for the quarter, hitting the consensus estimate of ($0.22). The business earned $12.11 million during the quarter. LENSAR had a negative trailing twelve-month return on equity of 40.53% and a negative net margin of 34.11%. How do I buy shares of LENSAR? Shares of LNSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LNSR) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENSAR, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
